Abstract
Purpose
This study was aimed to evaluate the effect and tolerability of bicalutamide 150 mg therapy in patients with castration-resistant prostate cancer (CRPC).
Methods
A total of 48 patients with histologically confirmed prostate cancer were included. They had been treated with continuous maximal androgen blockade therapy, but their serum prostate-specific antigen (PSA) increased after initial hormonal therapy. Patients were given bicalutamide (150 mg per day). Serum PSA testing was performed every 3 months. The response was defined according to PSA decline from baseline: PSA decline ≥85 % as complete response, ≥50 % but <85 % as partial response, and <50 % as failure. Response duration was defined as the time from PSA response until PSA increased ≥25 % or ≥2 ng/mL from the nadir. The potential predictive factors (Gleason score, clinical stage and serum PSA) were investigated.
Results
The time of follow-up was 3–30 months. A PSA decline ≥50 % was observed in 37 of 48 patients including 18 ≥ 50 % but <85 % and 19 ≥ 85 % responders. The median response duration was 12 months for partial responders and 20 months for complete responders. Patients with lower Gleason score, lower serum PSA and using flutamide as first-line nonsteroidal antiandrogen achieved more benefits. Moreover, bicalutamide 150 mg therapy was well tolerated.
Conclusions
Bicalutamide 150 mg therapy was an appropriate therapeutic method for patients of CRPC, especially for those with lower Gleason score, lower serum PSA and using flutamide as first-line nonsteroidal antiandrogen.
Similar content being viewed by others
References
Jemal A, Murray T, Ward E et al (2005) Cancer statistics 2005. CA Cancer J Clin 55:10–30
Lodde M, Lacombe L, Fradet Y (2010) Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology 76:1189–1193
Suzuki H, Okihara K, Miyake H et al (2008) Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180:921–927
Tanimoto T, Hori A, Kami M (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:1966
Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns EST (2009) Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 115:126–136
Stanbrough M, Bubley GJ, Ross K et al (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815–2825
Mohler JL (2008) Castration-recurrent prostate cancer is not androgen-independent, in hormonal carcinogenesis V. Springer, NewYork, pp 223–234
Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15:382–388
Klotz L, Drachenberg D, Singal R et al (2014) An open-label, phase 2 trial of bicalutamide dose escalation from 50 to 150 mg in men with CAB and castration resistance. A Canadian urology research consortium study. Prostate Cancer Prostatic Dis 17:320–324
Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin M-E (2011) Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer 9:95–103
Labrie F (2014) Prostate cancer: bicalutamide dose increase in castration-resistant disease. Nat Rev Urol
Kucuk O, Fisher E, Moinpour CM et al (2001) Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest oncology group study (SWOG 9235). Urology 58:53–58
Yates JW, Chalmer B, Mckegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224
Goa KL, Spencer CM (1998) Bicalutamide in advanced prostate cancer. Drugs Aging 12:401–422
Attard G, Richards J, De Bono JS (2011) New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 17:1649–1657
Ferraldeschi R, Pezaro C, Karavasilis V, De Bono J (2013) Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Annu Rev Med 64:1–13
Ahmed A, Ali S, Sarkar FH (2014) Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol 229:271–276
Taplin M-E, Bubley GJ, Shuster TD et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398
Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S (2013) Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 73:1291–1305
Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981–991
Schellhammer PF, Venner P, Haas GP et al (1997) Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157:1731–1735
Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025–1033
Figg WD, Sartor O, Cooper MR et al (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412–414
Scher HI, Liebertz C, Kelly WK et al (1997) Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15:2928–2938
Joyce R, Fenton MA, Rode P et al (1998) High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159:149–153
Ryan CJ, Small EJ (2003) Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 62:87–94
Hara T, Miyazaki J-I, Araki H et al (2003) Novel mutations of androgen receptor A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149–153
Taplin M-E, Bubley GJ, Ko Y-J et al (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511–2515
Hu X, Lazar MA (2000) Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab 11:6–10
Narimoto K, Mizokami A, Izumi K et al (2010) Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol 17:337–345
Kim J, Jia L, Stallcup M, Coetzee G (2005) The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol 34:107–118
Yu G, Traish AM (2011) Induced testosterone deficiency: from clinical presentation of fatigue, erectile dysfunction and muscle atrophy to insulin resistance and diabetes. Horm Mol Biol Clin Investig 8:425–430
Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175:27–34
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Su-bo Qian and Hai-bo Shen contributed equally to this work.
Rights and permissions
About this article
Cite this article
Qian, Sb., Shen, Hb., Cao, Qf. et al. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer. Int Urol Nephrol 47, 479–484 (2015). https://doi.org/10.1007/s11255-015-0919-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-015-0919-y